Research
Molecular
Tirzepatide was evaluated for its effects on cardiovascular and diabetic kidney disease biomarkers in overweight and obese adults with type 1 diabetes over a period of 21 months.
Practitioners may consider tirzepatide for managing cardiovascular and kidney health in overweight and obese patients with type 1 diabetes.
StrongSupportsmedium confidence
We evaluated CVD and DKD biomarkers with off-label long-term (21 months) use of tirzepatide in OW/OB adults with T1D.
Why this rating
The study involves long-term treatment and evaluation of biomarkers.
Source
Cardiovascular and Renal Biomarkers in Overweight and Obese Adults with Type 1 Diabetes Treated with Tirzepatide for 21 Months
Subhash Vishal Garg et al. · Diabetes Technology & Therapeutics · 2025
otherCited 18×
Read the paper This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →